A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)
November 5, 2022 | American Society of Nephrology (ASN) Kidney Week
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)
Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy
November 3, 2022 | American Society of Nephrology (ASN) Kidney Week
Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy
Role of APRIL in IgAN Pathophysiology
October 4, 2022 | Rare & Genetic Kidney Disease Drug Development Conference
Role of APRIL in IgAN Pathophysiology
Role of Complement Cascade in Glomerular Diseases
October 4, 2022 | Rare & Genetic Kidney Disease Drug Development Conference
Role of Complement Cascade in Glomerular Diseases
A potent anti-C5aR1 Antibody for Treatment of ANCA Associated Vasculitis
September 27, 2022 | Complement-based Drug Development Summit
A potent anti-C5aR1 Antibody for Treatment of ANCA Associated Vasculitis
Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance
June 4, 2022 | American Transplant Congress
Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance
A Novel IL-2 Mutein Selectively Expands Regulatory T Cells and Prolongs Skin Graft Survival
June 4, 2022 | American Transplant Congress
A Novel IL-2 Mutein Selectively Expands Regulatory T Cells and Prolongs Skin Graft Survival
Selective Regulatory T Cell Expansion by Novel IL-2 Mutein Prolongs Skin Transplant Survival
June 4, 2021 | American Transplant Congress
Selective Regulatory T Cell Expansion by Novel IL-2 Mutein Prolongs Skin Transplant Survival
Targeting C5aR1 for the Treatment of ANCA-associated Vasculitis
March 3, 2020 | Festival of Biologics
Targeting C5aR1 for the Treatment of ANCA-associated Vasculitis
Monovalent IgGs as a Tool for Characterizing Antibody Binding and Function
January 20, 2020 | Peptalk
